SCHEMBL26608491

SCHEMBL26608491

COc1ccc(COc2cc(Cl)nc(C)c2CO)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ POLB P06746 3/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.43
▸ PDE2A O00408 1/20 0.41
▸ MTNR1A P48039 1/20 0.40
▸ MTNR1B P49286 1/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ LMNA P02545 3/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ RHEB Q15382 2/20 0.39
▸ APP P05067 3/20 0.39
▸ NTRK1 P04629 1/20 0.39
▸ CSF1R P07333 1/20 0.39
▸ NTRK3 Q16288 1/20 0.39
▸ NTRK2 Q16620 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31517865 0.85 HTT (0.49) SMN1; SMN2LMNAMAPTHTTL3MBTL1
SCHEMBL26608385 0.80 MTNR1A (0.46) NPC1RAB9APOLBNPSR1MTNR1A
SCHEMBL26601614 0.80 POLB (0.49) NPC1RAB9APOLBMTNR1AMTNR1B
SCHEMBL26601891 0.79 NPSR1 (0.43) NPC1RAB9APOLBNPSR1MTNR1A
SCHEMBL24773216 0.79 PDE4A (0.40) NPC1RAB9APOLBMAPTHTT
SCHEMBL26601712 0.79 NPC1 (0.48) NPC1RAB9APOLBPDE2AL3MBTL1
SCHEMBL31015519 0.77 POLB (0.47) NPC1RAB9APOLBSMN1; SMN2LMNA
SCHEMBL25151518 0.77 GAA (0.53) NPC1RAB9APOLBNPSR1MTNR1A
SCHEMBL30593191 0.77 GAA (0.53) NPC1RAB9APOLBNPSR1MTNR1A
SCHEMBL31465398 0.77 NPC1 (0.47) NPC1RAB9APDE2ASMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-25 — — US disclosed
EP-4511115-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Vertex Pharmaceuticals Incorporated (US) 2025-02-26 — — EP disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed
WO-2023205468-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-10-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388543-A1 HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN SCN8A, SCN1B, SCN3A NPC1 169/4885RAB9A 1794/4885POLB 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback